24/07/2024
Cervical cancer remains a major public health issue worldwide, particularly affecting women in low- and middle-income countries. In 2022, cervical cancer was the fourth most common cancer among women globally, with approximately 660,000 new cases diagnosed. The year also saw a tragic loss of 350,000 lives due to this preventable disease (World Health Organization (WHO)) (CDC).
Causes and Risk Factors
The primary cause of cervical cancer is a persistent infection with high-risk types of human papillomavirus (HPV). HPV is an extremely common virus transmitted through sexual contact, and while most infections resolve spontaneously, persistent infections can lead to cervical cancer. Women living with HIV are at a significantly higher risk, being six times more likely to develop cervical cancer compared to women without HIV. Other risk factors include smoking, long-term use of oral contraceptives, and having multiple full-term pregnancies (World Health Organization (WHO)).
Prevention and Early Detection
Preventive measures and early detection are crucial in reducing the incidence and mortality of cervical cancer. The HPV vaccine, which protects against the high-risk HPV types 16 and 18, is highly effective and is recommended for girls aged 9-14 before they become sexually active. As of 2023, six HPV vaccines are available globally, and some countries also vaccinate boys to further reduce HPV prevalence and prevent related cancers in men (World Health Organization (WHO)) (CDC).
Despite these efforts, significant challenges remain, particularly in resource-limited settings where access to healthcare services is limited. Organizations like Unitaid are investing in innovative technologies and programs to improve cervical cancer prevention and treatment in these areas, aiming to make a substantial impact on global health (Unitaid).
